alleen voor onderzoeksdoeleinden

Tauroursodeoxycholic Acid (TUDCA) ER Stress Inhibitor

Cat.nr.: S3654

Tauroursodeoxycholic Acid (TUDCA) is het taurineconjugaat van ursodeoxycholzuur (UDCA) en fungeert als mitochondriale stabilisator en anti-apoptotisch middel in verschillende modellen van neurodegeneratieve ziekten, waaronder AD, de ziekte van Parkinson (PD) en de ziekte van Huntington (HD).
Tauroursodeoxycholic Acid (TUDCA) ER stress Remmer Chemical Structure

Chemische structuur

Molecuulgewicht: 499.70

Spring naar

Kwaliteitscontrole (Quality Control)

Batch: Zuiverheid: 99.97%
99.97

Celkweek, behandeling & werkzame concentratie
(Cell Culture, Treatment & Working Concentration)

Cellijnen Assaytype Concentratie Incubatietijd Formulering Activiteitsbeschrijving PMID
CHO cells Function assay Agonist activity at human TGR5 expressed in CHO cells by luciferase assay, EC50=30 μM 18307294
Sf9 Function assay TP_TRANSPORTER: uptake in membrane vesicles from Bsep-expressing Sf9 cells, Km=4.1μM 10648470
MDCK Function assay TP_TRANSPORTER: uptake in Oatp3-expressing MDCK cells, Km=6.6μM 11093941
HEK293 Function assay 90 mins Inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in choline release from LPC measured every 30 secs for 90 mins by HVA based fluorescence assay, IC50=10.3μM 28165241
Sf9 Function assay TP_TRANSPORTER: uptake in membrane vesicles isolated from Bsep-expressing Sf9 cells, Km=11.9μM 12404240
CHO Function assay TP_TRANSPORTER: uptake in Ntcp-expressing CHO cells, Km=14μM 9486191
COS Function assay TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells, Ki=28μM 9458785
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of CHOP mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as increase in XBPu mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against DCA-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of XBPs mRNA levels after 6 hrs 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as reduction in XBPs/XBPu ratio after 6 hrs 27729186
HuH7 Cytoprotective assay 1 mM 24 hrs Cytoprotective activity against DCA-induced cell death in human HuH7 cells assessed as increase in cell viability at 1 mM preincubated with cells followed by DCA addition measured after 24 hrs by MTT/INCELL assay 27729186
HuH7 Cytoprotective assay 6 hrs Cytoprotective activity against tunicamycin-induced ER stress in human HuH7 cells assessed as inhibition of BIP/GRP78 mRNA levels after 6 hrs 27729186
HEK293 Function assay Non-competitive inhibition of human ATX expressed in HEK293 Flp-In cells assessed as decrease in LPC hydrolysis by Lineweaver-Burk plot analysis 28165241
Klik om meer experimentele gegevens over cellijnen te bekijken

Chemische informatie, opslag en stabiliteit (Chemical Information, Storage & Stability)

Molecuulgewicht 499.70 Formule

C26H45NO6S

Opslag (vanaf de datum van ontvangst)
CAS-nr. 14605-22-2 SDF downloaden Opslag van stamoplossingen

Oplosbaarheid (Solubility)

In vitro
Batch:

DMSO : 100 mg/mL (200.12 mM)
(Met vocht verontreinigd DMSO kan de oplosbaarheid verminderen. Gebruik verse, watervrije DMSO.)

Water : 100 mg/mL

Ethanol : 50 mg/mL

Molariteitscalculator

Massa Concentratie Volume Molecuulgewicht
Verdunningscalculator Molecuulgewichtcalculator

In vivo
Batch:

In vivo formulatiecalculator (heldere oplossing)

Stap 1: Voer onderstaande informatie in (Aanbevolen: een extra dier om rekening te houden met verlies tijdens het experiment)

mg/kg g μL

Stap 2: Voer de in vivo formulering in (Dit is alleen de calculator, geen formulering. Neem eerst contact met ons op als er geen in vivo formulering is in de sectie oplosbaarheid.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Berekeningsresultaten:

Werkconcentratie: mg/ml;

Methode voor het bereiden van DMSO-moedervloeistof: mg geneesmiddel vooropgelost in μL DMSO ( Concentratie moedervloeistof mg/mL, Neem eerst contact met ons op als de concentratie de DMSO-oplosbaarheid van de batch van het geneesmiddel overschrijdt. )

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toeμL PEG300, mengen en verhelderen, daarna toevoegenμL Tween 80, mengen en verhelderen, daarna toevoegen μL ddH2O, mengen en verhelderen.

Methode voor het bereiden van in vivo formulering: Neem μL DMSO moedervloeistof, voeg daarna toe μL Maïsolie, mengen en verhelderen.

Opmerking: 1. Zorg ervoor dat de vloeistof helder is voordat u het volgende oplosmiddel toevoegt.
2. Zorg ervoor dat u het/de oplosmiddel(en) in de juiste volgorde toevoegt. U moet ervoor zorgen dat de verkregen oplossing, bij de vorige toevoeging, een heldere oplossing is voordat u verdergaat met het toevoegen van het volgende oplosmiddel. Fysieke methoden zoals vortexen, ultrasoon of een warmwaterbad kunnen worden gebruikt om het oplossen te bevorderen.

Werkingsmechanisme (Mechanism of Action)

In vitro
Tauroursodeoxycholic acid (TUDCA) is an endogenous hydrophilic tertiary bile acid produced in humans at a low level. In ER stress conditions, treatment with this compound reduces the activation of ER stress-associated proteins, including GRP78, PERK, eIF2α, ATF4, IRE1α, JNK, p38, and CHOP, and inhibits the dissociation between GRP78 and PERK, resulting in reduced ER stress-mediated cell death. It also increases PrPC (Cellular prion protein) expression. TUDCA regulates stem cell differentiation into various lineages such as adipogenic and osteogenic lineages. It attenuates ER stress, prevents unfolded protein response dysfunction, and stabilizes mitochondria. Under ER stress, treatment with this compound significantly increases the expression of BCL-2 and significantly decreases the expression of Bax, cleaved caspase-3, and cleaved PARP-1, compared with that of untreated cells.
In vivo
Tauroursodeoxycholic Acid (TUDCA) is effective for treating cholestatic liver diseases and also has an ameliorating effect on several diseases, including neurodegenerative diseases, osteoarthritis, vascular diseases, and diabetes. In a murine hindlimb ischemia model, TUDCA-treated mesenchymal stem cells (MSCs) transplantation augments the blood perfusion ratio, vessel formation, and transplanted cell survival more than untreated MSC transplantation does. Augmented functional recovery following MSC transplantation is blocked by PrPC downregulation. Several studies in animals have shown that this compound, an endogenous ambiphilic bile acid, can inhibit unfolded protein response dysfunction and ameliorate ER stress. Its administration attenuates HDM-induced ER stress, airway inflammation, mucus metaplasia, airway remodeling, and methacholine-induced AHR.
Referenties

Toepassingen (Applications)

Methoden Biomarkers Afbeeldingen PMID
Western blot RIPK1 / RIPK3 / p-RIPK1 / p-RIPK3 CHOP / Caspase-12 / Cleaved caspase-12 PrPc p-Akt / Akt
S3654-WB4
29721028
Growth inhibition assay Cell viability
S3654-viability1
30038553

Informatie over klinische proeven (Clinical Trial Information)

(gegevens van https://clinicaltrials.gov, bijgewerkt op 2026-04-21)

NCT-nummer Werving Aandoeningen Sponsor/medewerkers Startdatum Fasen
NCT07328009 RECRUITING
Hepato Cellular Carcinoma (HCC)
Fudan University
2026-01-19 PHASE2
NCT06025630 RECRUITING
Hypertension
University of North Texas Health Science Center
2023-08-15 PHASE1; PHASE2
NCT07457632 NOT_YET_RECRUITING
Diabetic Macular Edema (DME)
University of Alabama at Birmingham
2026-10-01 PHASE2
NCT07100392 RECRUITING
Hepatocellular Carcinoma (HCC)
Fudan University
2025-08-14 PHASE2
NCT07064668 NOT_YET_RECRUITING
Hepatocellular Carcinoma
Tongji Hospital
2025-07-30 PHASE2
NCT07517276 NOT_YET_RECRUITING
Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
Peking University First Hospital
2026-04-02 PHASE2